3,4-dihydroxybenzohydroxamic acid has been researched along with Brain Neoplasms in 3 studies
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Figul, M | 1 |
| Söling, A | 1 |
| Dong, HJ | 1 |
| Chou, TC | 1 |
| Rainov, NG | 1 |
| Horvath, Z | 2 |
| Höchtl, T | 1 |
| Bauer, W | 2 |
| Fritzer-Szekeres, M | 2 |
| Elford, HL | 1 |
| Szekeres, T | 2 |
| Tihan, T | 2 |
| Hoechtl, T | 1 |
| Saiko, P | 1 |
3 other studies available for 3,4-dihydroxybenzohydroxamic acid and Brain Neoplasms
| Article | Year |
|---|---|
Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells.
Topics: Antineoplastic Agents, Alkylating; Benzamidines; Brain Neoplasms; Dacarbazine; Drug Synergism; Enzym | 2003 |
Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cere | 2004 |
Combination chemotherapy of BCNU and Didox acts synergystically in 9L glioma cells.
Topics: Animals; Anti-Infective Agents, Local; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Ant | 2004 |